MRNA — what changed in the latest 10-Q
A section-by-section comparison of MRNA's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-07-31 vs the prior 10-Q · 2026-05-01
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~1 | 0 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 1 |
| Legal proceedings | Text added/removed | +1 | −2 | ~1 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +8 | −1 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-07-31
In July 2026, Translate Bio, Inc., Translate Bio MA, Inc., Sanofi Vaccines US, Inc., and VaxServe, Inc. (all subsidiaries of Sanofi SA), filed a complaint against us in the U.S. District Court for the District of New Jersey asserting that our manufacture and sale of our COVID and RSV vaccines infrin…
Text removed vs the prior filing · source: 10-Q · 2026-05-01
As more fully described in our 2025 Form 10-K, Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) brought patent infringement actions against us in various jurisdictions, including in the U.S. District Court for the District of Delaware. On March 3, 2026, we entered into a…
In April 2026, CureVac SE and CureVac Manufacturing GmbH filed a complaint against us in the U.S. District Court for the District of Delaware asserting that our manufacture and sale of Spikevax willfully infringes U.S. patents directed to RNA production methods and compositions with RNA encoding mod…
Other information
Text added vs the prior filing · source: 10-Q · 2026-07-31
During the three months ended June 30, 2026, the following directors and officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) of the Company took the following actions regarding trading arrangements with respect to our securities:
On May 4, 2026, Stéphane Bancel, our Chief Executive Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c), which had been entered into on November 28, 2025, and was scheduled to commence as early as May 13, 2026, with a termination date of …
Mr. Bancel has two stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase 558,394 shares and an option to purchase 193,321 shares. Mr. Bancel also has a stock option award to purchase 642,201 shares that will reach its ten-year expiration on…
On May 4, 2026, Mr. Bancel adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). Between August 5, 2026, and February 26, 2027, the Bancel 10b5-1 Plan provides for the exercise of the Bancel Expiring Options and the sale of the …
Stephen Hoge, our President, has a stock option award to purchase 458,715 shares that will reach its ten-year expiration on February 23, 2027, and a stock option to purchase 1,834,862 shares that will reach its ten-year expiration on October 3, 2027 (together, the Hoge Expiring Options). On June 15,…
Text removed vs the prior filing · source: 10-Q · 2026-05-01
None of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter …
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice